Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer

Cancer Epidemiology

Volumn 33, Issue 2, 2009, Pages 137-141

  Okamura, Keigo ^a   Koike, Hidekazu ^a   Sekine, Yoshitaka ^a   Matsui, Hiroshi ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Renal cancer; Splice variants; Survivin

Indexed keywords

SMALL INTERFERING RNA; SURVIVIN; SURVIVIN 2ALPHA; SURVIVIN 2B; SURVIVIN DELTAEX3; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CELL STRAIN CAKI 1; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; KIDNEY CELL; MALE; NEPHRECTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING;

ADULT; AGED; ALTERNATIVE SPLICING; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 68149134689     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.06.005     Document Type: Article

References (33)

1. Altieri D.C., and Marchisio P.C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79 (1999) 1327-1333
2. Zaffaroni N., Pennati M., and Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 9 (2005) 360-372
3. Takai N., Miyazaki T., Nishida M., Nasu K., and Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 184 (2002) 105-116
4. Dong Y., Sui L., Watanabe Y., Sugimoto K., and Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 22 (2002) 2377-2383
5. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
6. Monzó M., Rosell R., Felip E., Astudillo J., Sánchez J.J., and Maestre J. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J Clin Oncol 17 (1999) 2100-2104
7. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6 (2000) 127-134
8. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., and Isogai E. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 (2000) 617-623
9. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., and Toyama T. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95 (2001) 92-95
10. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999) 6097-6102
11. Mahotka C., Krieg T., Krieg A., Wenzel M., Suschek C.V., and Heydthausen M. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100 (2002) 30-36
12. Caldas H., Honsey L.E., and Altura R.A. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4 (2005) 11
13. Caldas H., Jiang Y., Holloway M.P., Fangusaro J., Mahotka C., and Conway E.M. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24 (2005) 1994-2007
14. Meng H., Lu C., Mabuchi H., and Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 216 (2004) 147-155
15. Span P.N., Tjan-Heijnen V.C., Heuvel J.J., de Kok J.B., Foekens J.A., and Sweep F.C. Do the surviving splice variants modulate or add to the prognostic value of total survivin in breast cancer?. Clin Chem 52 (2006) 1693-1700
16. Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281 (2006) 1286-1295
17. Kaur P., Kallakury B.S., Sheehan C.E., Fisher H.A., Kaufman Jr. R.P., and Ross J.S. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128 (2004) 39-43
18. Olie R.A., Simões-Wüst A.P., Baumann B., Leech S.H., Fabbro D., and Stahel R.A. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (2000) 2805-2809
19. Pennati M., Binda M., Colella G., Zoppe' M., Folini M., and Vignati S. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23 (2004) 386-394
20. Hayashi N., Asano K., Suzuki H., Yamamoto T., Tanigawa N., and Egawa S. Adenoviral infection of survivin antisense sensitizes prostate cancer to etoposide in vivo. Prostate 65 (2005) 10-19
21. Zhang M., Mukherjee N., Bermudez R.S., Latham D.E., Delaney M.A., and Zietman A.L. Adenovirus-mediated inhibition of survivin expression sensitize human prostate cancer cells to paclitaxel in vitro an in vivo. Prostate 64 (2005) 293-302
22. Pennati M., Binda M., Colella G., Folini M., Citti L., and Villa R. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120 (2003) 648-654
23. Suzuki K., Koike H., Matsui H., Ono Y., Hasumi M., Nakazato H., et al. a soy isofravone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 99 (2002) 846-852
24. Sato A., Ito K., Asano T., Sumitomo M., Asano T., and Hayakawa M. Topotecan and small interfering RNA suppress survivin expression synergistically in Cali-1 renal cancer cells: direct suppression of survivin and enhancement of transfection efficiency by topotecan. Int J Oncol 32 (2008) 171-176
25. Parker A.S., Kosari F., Lohse C.M., Houston Thompson R., Kwon E.D., and Murphy L. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 107 (2006) 37-45
26. Taubert H., Kappler M., Bache M., Bartel F., Köhler T., and Lautenschläger C. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 24 (2005) 5258-5261
27. Futakuchi H., Ueda M., Kanda K., Fujino K., Yamaguchi H., and Noda S. Transcriptional expression of survivin and its splice variants in cervical carcinomas. Int J Gynecol Cancer 17 (2007) 1092-1098
28. Takamizawa S., Scott D., Wen J., Grundy P., Bishop W., Kimura K., et al. The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg 36 (2001) 37-42
29. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12 (2005) 217-227
30. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of BCL-2 FLIP or IAPs(XIAP and Survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11 (2004) 915-923
31. Sato A., Oya M., Mizuno R., Horiguchi Y., Umezawa K., Hayakawa M., et al. Survivin associates with cell proliferation in renal cell cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-γ and a novel NF-κB inhibitor. Int J Oncol 28 (2006) 841-846
32. Sato A., Ito K., Asano T., Sumitomo M., Asano T., and Hayakawa M. Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. Int J Oncol 30 (2007) 695-700
33. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26 (2008) 5198-5203